Opinion|Videos|May 2, 2025
Balancing Clinical and Patient-Centered Factors in 1L EGFRm NSCLC Treatment
Panelists discuss how patient-centered factors are crucial in shared decision-making for first-line (1L) treatment, with a potential default approach of offering combination therapy with an option to choose osimertinib monotherapy.
Advertisement
Episodes in this series
Patient-Centered Factors in Treatment Decision-Making
Main Discussion Topics:
- Incorporating patient goals and preferences into treatment selection
- Approaches to shared decision-making in time-limited clinical visits
- Use of risk stratification strategies to guide treatment intensity
Key Points for Physicians:
- With significant survival data, combination therapy may become the default with an “opt-out” approach
- Liquid biopsy (circulating tumor DNA clearance) can help stratify patients who might benefit from treatment escalation
- All treatments (chemotherapy, amivantamab, EGFR inhibitors) will likely be used at some point in the disease course
Notable Insights:
Treatment sequencing must consider that not all patients receive 2L therapy, making it critical to optimize 1L treatment selection.
Clinical Significance:
A nuanced approach to 1L therapy involves balancing evidence-based recommendations with individualized assessment of risk and patient preferences.
Advertisement
Related to this article
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5